Literature DB >> 20463022

Pro-tumorigenic effects of miR-31 loss in mesothelioma.

Sergey V Ivanov1, Chandra M V Goparaju, Peter Lopez, Jiri Zavadil, Ginat Toren-Haritan, Shai Rosenwald, Moshe Hoshen, Ayelet Chajut, Dalia Cohen, Harvey I Pass.   

Abstract

The human genome encodes several hundred microRNA (miRNA) genes that produce small (21-23n) single strand regulatory RNA molecules. Although abnormal expression of miRNAs has been linked to cancer progression, the mechanisms of this dysregulation are poorly understood. Malignant mesothelioma (MM) of pleura is an aggressive and highly lethal cancer resistant to conventional therapies. We and others previously linked loss of the 9p21.3 chromosome in MM with short time to tumor recurrence. In this study, we report that MM cell lines derived from patients with more aggressive disease fail to express miR-31, a microRNA recently linked with suppression of breast cancer metastases. We further demonstrate that this loss is due to homozygous deletion of the miR-31-encoding gene that resides in 9p21.3. Functional assessment of miR-31 activity revealed its ability to inhibit proliferation, migration, invasion, and clonogenicity of MM cells. Re-introduction of miR-31 suppressed the cell cycle and inhibited expression of multiple factors involved in cooperative maintenance of DNA replication and cell cycle progression, including pro-survival phosphatase PPP6C, which was previously associated with chemotherapy and radiation therapy resistance, and maintenance of chromosomal stability. PPP6C, whose mRNA is distinguished with three miR-31-binding sites in its 3'-untranslated region, was consistently down-regulated by miR-31 introduction and up-regulated in clinical MM specimens as compared with matched normal tissues. Taken together, our data suggest that tumor-suppressive propensity of miR-31 can be used for development of new therapies against mesothelioma and other cancers that show loss of the 9p21.3 chromosome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463022      PMCID: PMC2906272          DOI: 10.1074/jbc.M110.100354

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.

Authors:  Collins A Karikari; Michael Mullendore; James R Eshleman; Pedram Argani; Lorenzo M Leoni; Shrikanta Chattopadhyay; Manuel Hidalgo; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2005-12       Impact factor: 6.261

2.  Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.

Authors:  Eva Grafström; Suzanne Egyházi; Ulrik Ringborg; Johan Hansson; Anton Platz
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

Review 3.  The regulation of INK4/ARF in cancer and aging.

Authors:  William Y Kim; Norman E Sharpless
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

4.  Chromosomal imbalances in brain metastases of solid tumors.

Authors:  I Petersen; A Hidalgo; S Petersen; K Schlüns; C Schewe; M Pacyna-Gengelbach; A Goeze; B Krebber; T Knösel; O Kaufmann; J Szymas; A von Deimling
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

5.  Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.

Authors:  José M García-Castellano; Alberto Villanueva; John H Healey; Rebecca Sowers; Carlos Cordon-Cardo; Andrew Huvos; Joseph R Bertino; Paul Meyers; Richard Gorlick
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

6.  hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

Authors:  Harvey I Pass; Chandra Goparaju; Sergey Ivanov; Jessica Donington; Michele Carbone; Moshe Hoshen; Dalia Cohen; Ayelet Chajut; Shai Rosenwald; Harel Dan; Sima Benjamin; Ranit Aharonov
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

Review 8.  3p21.3 tumor suppressor cluster: prospects for translational applications.

Authors:  Lin Ji; John D Minna; Jack A Roth
Journal:  Future Oncol       Date:  2005-02       Impact factor: 3.404

9.  GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information.

Authors:  Ruben Nogales-Cadenas; Pedro Carmona-Saez; Miguel Vazquez; Cesar Vicente; Xiaoyuan Yang; Francisco Tirado; Jose María Carazo; Alberto Pascual-Montano
Journal:  Nucleic Acids Res       Date:  2009-05-22       Impact factor: 16.971

10.  Protocol: a highly sensitive RT-PCR method for detection and quantification of microRNAs.

Authors:  Erika Varkonyi-Gasic; Rongmei Wu; Marion Wood; Eric F Walton; Roger P Hellens
Journal:  Plant Methods       Date:  2007-10-12       Impact factor: 4.993

View more
  63 in total

1.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.

Authors:  Didier Jean; Emilie Thomas; Elodie Manié; Annie Renier; Aurélien de Reynies; Céline Lecomte; Pascal Andujar; Jocelyne Fleury-Feith; Françoise Galateau-Sallé; Marco Giovannini; Jessica Zucman-Rossi; Marc-Henri Stern; Marie-Claude Jaurand
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 2.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 3.  Reading between the lines; understanding drug response in the post genomic era.

Authors:  Constantine C Alifrangis; Ultan McDermott
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

Review 4.  Role of microRNAs in malignant mesothelioma.

Authors:  A Truini; S Coco; A Alama; C Genova; C Sini; M G Dal Bello; G Barletta; E Rijavec; G Burrafato; F Boccardo; F Grossi
Journal:  Cell Mol Life Sci       Date:  2014-02-23       Impact factor: 9.261

5.  Adaptation of HepG2 cells to a steady-state reduction in the content of protein phosphatase 6 (PP6) catalytic subunit.

Authors:  Joan M Boylan; Arthur R Salomon; Umadevi Tantravahi; Philip A Gruppuso
Journal:  Exp Cell Res       Date:  2015-05-18       Impact factor: 3.905

Review 6.  MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets.

Authors:  Glen Reid
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

7.  Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.

Authors:  Rosário Pinto-Leite; Isabel Carreira; Joana Melo; Susana Isabel Ferreira; Ilda Ribeiro; Jaqueline Ferreira; Marco Filipe; Carina Bernardo; Regina Arantes-Rodrigues; Paula Oliveira; Lúcio Santos
Journal:  Tumour Biol       Date:  2014-01-24

8.  MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Authors:  Michaela B Kirschner; Yuen Yee Cheng; Nicola J Armstrong; Ruby C Y Lin; Steven C Kao; Anthony Linton; Sonja Klebe; Brian C McCaughan; Nico van Zandwijk; Glen Reid
Journal:  Mol Oncol       Date:  2014-12-02       Impact factor: 6.603

9.  Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells.

Authors:  Sichuan Xi; Maocheng Yang; Yongguang Tao; Hong Xu; Jigui Shan; Suzanne Inchauste; Mary Zhang; Leandro Mercedes; Julie A Hong; Mahadev Rao; David S Schrump
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  MiR-351 transiently increases during muscle regeneration and promotes progenitor cell proliferation and survival upon differentiation.

Authors:  Yongxin Chen; David W Melton; Jonathan A L Gelfond; Linda M McManus; Paula K Shireman
Journal:  Physiol Genomics       Date:  2012-09-11       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.